Literature DB >> 9370043

Chronic lymphocytic leukaemia: the nature of the leukaemic cell.

T J Hamblin1, D G Oscier.   

Abstract

Far from being the boring, inactive, inert lymphocyte that haematologists of old perceived it to be, the chronic lymphocytic leukaemia (CLL) cell has set us many complex problems. The cell is apparently stuck in G0 in cell cycle, yet expresses many activation markers. The cells apparently manufacture many cytokines and respond in vitro to even more, yet cells entering even G1 are few. The cell surface marker profile is unique. There is apparently no normal equivalent of the CLL cell. In part, this may be because the cell is malignant; malignant cells often express aberrant markers. Consistent chromosomal abnormalities are emerging but we have no idea how these abnormalities translate into molecular mistakes that dictate the peculiar nature of the cell. CLL cells carry a characteristics set of adhesion molecules, but we cannot read their homing and recycling instructions. The outstanding irregularities of the CLL cell are its CD5 positivity and its sparse surface immunoglobulin. This ought to translate as an anergic B1 cell, perhaps programmed for autoimmunity. If the tumour cell were responsible for the patient's production of immunoglobulin or secretion of autoantibodies, then a pattern might have emerged. Alas, these are the product of the normal B cells. How the CLL cell induces these complications is unknown. Thus, despite the information contained in this review, the CLL cell remains a puzzle.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9370043     DOI: 10.1016/s0268-960x(97)90007-2

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  17 in total

1.  Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis.

Authors:  Antonella Contri; Anna Maria Brunati; Livio Trentin; Anna Cabrelle; Marta Miorin; Luca Cesaro; Lorenzo A Pinna; Renato Zambello; Gianpietro Semenzato; Arianna Donella-Deana
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

2.  Dipeptidyl peptidase 2 apoptosis assay determines the B-cell activation stage and predicts prognosis in chronic lymphocytic leukemia.

Authors:  Alexey V Danilov; Olga V Danilova; Jennifer R Brown; Arthur Rabinowitz; Andreas K Klein; Brigitte T Huber
Journal:  Exp Hematol       Date:  2010-09-24       Impact factor: 3.084

3.  Primary del 17 chronic lymphocytic leukaemia lymphocytes are hypersensitive to dasatinib in vitro.

Authors:  Lilian Amrein; Lawrence Panasci; Spencer B Gibson; James B Johnston; Denis Soulières; Raquel Aloyz
Journal:  Br J Haematol       Date:  2009-09-02       Impact factor: 6.998

4.  Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells.

Authors:  Monika Podhorecka; Dorota Halicka; Piotr Klimek; Malgorzata Kowal; Sylwia Chocholska; Anna Dmoszynska
Journal:  Ann Hematol       Date:  2010-05-25       Impact factor: 3.673

5.  Interphase Molecular Cytogenetic Detection Rates of Chronic Lymphocytic Leukemia-Specific Aberrations Are Higher in Cultivated Cells Than in Blood or Bone Marrow Smears.

Authors:  Eyad Alhourani; Rouben Aroutiounian; Tigran Harutyunyan; Anita Glaser; Cordula Schlie; Beate Pohle; Thomas Liehr
Journal:  J Histochem Cytochem       Date:  2016-06-17       Impact factor: 2.479

6.  Resveratrol increases rate of apoptosis caused by purine analogues in malignant lymphocytes of chronic lymphocytic leukemia.

Authors:  Monika Podhorecka; Dorota Halicka; Piotr Klimek; Malgorzata Kowal; Sylwia Chocholska; Anna Dmoszynska
Journal:  Ann Hematol       Date:  2010-08-17       Impact factor: 3.673

7.  HS1, a Lyn kinase substrate, is abnormally expressed in B-chronic lymphocytic leukemia and correlates with response to fludarabine-based regimen.

Authors:  Federica Frezzato; Cristina Gattazzo; Veronica Martini; Valentina Trimarco; Antonella Teramo; Samuela Carraro; Anna Cabrelle; Elisa Ave; Monica Facco; Renato Zambello; Elena Tibaldi; Anna Maria Brunati; Gianpietro Semenzato; Livio Trentin
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

8.  The rate of in vitro fludarabine-induced peripheral blood and bone marrow cell apoptosis may predict the chemotherapy outcome in patients with chronic lymphocytic leukemia.

Authors:  Monika Podhorecka; Piotr Klimek; Sylwia Chocholska; Agnieszka Szymczyk; Arkadiusz Macheta; Malgorzata Kowal; Anna Dmoszynska; Marek Hus
Journal:  Eur J Clin Pharmacol       Date:  2015-07-05       Impact factor: 2.953

9.  [Not Available].

Authors:  Lyse A Norian; Tamara A Kucaba; James K Earel; Tina Knutson; Rebecca L Vanoosten; Thomas S Griffith
Journal:  J Oncol       Date:  2009-06-14       Impact factor: 4.375

10.  Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia.

Authors:  A Olsson; M Norberg; A Okvist; K Derkow; A Choudhury; G Tobin; F Celsing; A Osterborg; R Rosenquist; M Jondal; L M Osorio
Journal:  Br J Cancer       Date:  2007-08-28       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.